Kampo Clinical Center, Department of General Internal Medicine, Hiroshima University Hospital, Hiroshima, Japan.
Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Osaka, Japan.
Medicine (Baltimore). 2022 Jul 15;101(28):e29748. doi: 10.1097/MD.0000000000029748.
It is expected that a low-toxicity natural compound like Kampo formulas would exhibit a preventive effect on COVID-19, in a global outbreak of coronavirus disease 2019 (COVID-19). Although the biological properties and safety of the representative Kampo, Hochuekkito (HET), and Kakkonto (KKT) have been confirmed in various animal model experiments and clinical studies, and in a few human studies to induce biological effects on various infectious diseases without significant toxicity, it is unclear whether HET and KKT are safe and effective for COVID-19 prevention. We summarized the clinical characteristics of HCWs and the preventive effects of HET and KKT. We performed a retrospective, single-center, cohort study that included 175 HCWs (aged 21-77 years) from a total number of 217 in a hospital with a history of COVID-19 cluster infection. In total, 175 HCWs were tested for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies. We identified 27 patients (median age: 49 ± 10.7 years) who were diagnosed with COVID-19. The patients in the group that had a body mass index ≥ 25 had a high COVID-19 infection risk, while those in the group with a Kampo formula adherence rate ≥ 40% had a low COVID-19 risk. Patients in the group with an adherence rate ≥ 40%, as well as those in the current alcohol consumption group, were at a low risk of developing severe COVID-19. In conclusion, HET and KKT may have prevented the onset or worsening of COVID-19, which could be clinically used. Obesity might have increased the patients' susceptibility to COVID-19 and the disease severity.
预计像汉方药方剂这样的低毒性天然化合物将对 2019 年冠状病毒病(COVID-19)的全球大流行产生预防作用。虽然代表性汉方 Hochuekkito(HET)和 Kakkonto(KKT)的生物学特性和安全性已在各种动物模型实验和临床研究中得到证实,并且在少数诱导对各种传染病产生生物学作用而无明显毒性的人体研究中得到证实,但尚不清楚 HET 和 KKT 是否对 COVID-19 的预防安全有效。我们总结了 HCWs 的临床特征以及 HET 和 KKT 的预防作用。我们进行了一项回顾性、单中心队列研究,该研究纳入了一家有 COVID-19 集群感染史的医院的 175 名 HCWs(年龄 21-77 岁)。共有 175 名 HCWs 接受了严重急性呼吸冠状病毒 2(SARS-CoV-2)抗体检测。我们共发现 27 名 COVID-19 患者(中位年龄:49±10.7 岁)。体重指数≥25 的患者 COVID-19 感染风险较高,而汉方方剂服用率≥40%的患者 COVID-19 风险较低。汉方方剂服用率≥40%的患者以及目前饮酒的患者患严重 COVID-19 的风险较低。总之,HET 和 KKT 可能预防了 COVID-19 的发病或恶化,这可能在临床上得到应用。肥胖可能增加了患者对 COVID-19 的易感性和疾病严重程度。